Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Stephen BagleyDivision of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. [email protected]Meghan LogunDepartment of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAJoseph A. FraiettaCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAXin WangDepartment of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAArati DesaiDivision of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USALinda J. BagleyDepartment of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAAli NabavizadehDepartment of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USADanuta JarochaCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USARene MartinsCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAEileen MaloneyDepartment of Neurosurgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USALester LledoCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USACarly SteinCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAAmy MarshallCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USARachel LeskowitzCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAJulie K. JadlowskyCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAShannon ChristensenCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USABike Su OnerCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAGabriela PlesaCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAAndrea BrennanCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAVanessa GonzalezCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAFang ChenCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAYusha SunDepartment of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAWhitney L. GladneyKite Pharma, a Gilead Company, Santa Monica, CA, USADavid M. BarrettKite Pharma, a Gilead Company, Santa Monica, CA, USAMacLean P. NasrallahDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAWei‐Ting HwangDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAGuo‐li MingDepartment of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAHongjun SongDepartment of Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USADonald L. SiegelCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USACarl H. JuneCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAElizabeth O. HexnerCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAZev A. BinderCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USADonald M. O’RourkeCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
2024en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0